SELLAS Life Sciences Group, Inc. (SLS)
| Market Cap | 138.58M |
| Revenue (ttm) | 9.50M |
| Net Income (ttm) | -15.21M |
| Shares Out | 15.27M |
| EPS (ttm) | -1.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,828 |
| Open | 8.60 |
| Previous Close | 8.72 |
| Day's Range | 8.56 - 8.80 |
| 52-Week Range | 2.33 - 19.38 |
| Beta | 1.71 |
| Analysts | Buy |
| Price Target | 18.50 (+111.2%) |
| Est. Earnings Date | Nov 12, 2021 |
About SLS
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b c...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SLS stock is "Buy." The 12-month stock price forecast is 18.50, which is an increase of 111.19% from the latest price.
News
SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer...
SELLAS Life Sciences Announces Settlement of Derivative Litigation
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cance...
SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cance...
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cancer
SELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021
Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee
Sellas Life Sciences Breaks Out Of Pennant Pattern: Technical Levels To Watch
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares were trading lower Wednesday after the company released updated clinical and initial immunobiological data from a Phase 1/2 clinical trial ofits lead...
SELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of G...
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up
SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined wit...
Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care...
SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer...
Sellas Life Sciences Stock May Have Broken Out Of Pennant Pattern: What's Next?
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) shares rallied Tuesday as retail traders try to push the stock higher. The stock is likely continuing its momentum after the company secured a U.S. patent fo...
What's Up With Sellas Life Sciences Stock Today?
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher by 8.3% at $8.24 after the company reported first-quarter EPS results up from last year. Sellas Life Sciences reported quarterly los...
SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Galinpepimut-S (GPS) i...
SELLAS Life Sciences to Host Shareholder Update Call on June 3rd
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer ...
SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update
Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercialization of Ga...
SELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on Mar...
NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cance...
SLS Stock: 8 Things to Know About SELLAS Life Sciences as It Enjoys Reddit Bump
Shares of SLS stock are up after SELLAS Life Sciences was mentioned heavily on Reddit. Who is this company?
SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe -
Shares of Startup Biotechs Soar on Cancer Study Results
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching for ...
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors i...
- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks and 100% Progression ...
SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million
- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing -
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of nove...
Why 3 Health Care Stocks Are Moving: Tv Therapeutics, Solid Biosciences, Sellas Life Sciences
Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction...
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with...
– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –
SLS Stock: Why SELLAS Life Sciences Is Surging Today
SLS stock is surging today as investors grow interest in a cancer vaccine from SELLAS Life Sciences in the wake of a rally in GLSI stock. The post SLS Stock: Why SELLAS Life Sciences Is Surging Today ap...
SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of G...
- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties -